drugset / Trial / NCT05144139
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
RandomizedSequentialDouble-blindPrevention
Summary
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
Timeline
- Start
- 2021-12-03
- Primary completion
- 2022-08-28
- Completion
- 2022-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT162b2 | Messenger RNA (mRNA) | 25 ug | Intramuscular |
| Subject | BNT162b2 | Messenger RNA (mRNA) | 45 ug | Intramuscular |